SUSVIMO: payments to doctors
Payments that named SUSVIMO as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $2.3M
- Providers
- 1,902
- Transactions
- 5,864
- Average per transaction
- $392
The per-transaction average — $392 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,902 providers the average total is $1,208, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,812,576 | 78.9% |
| Genentech, Inc. | $298,079 | 13.0% |
| F. Hoffmann-la Roche AG | $132,288 | 5.8% |
| Roche Products Limited | $44,142 | 1.9% |
| Hoffmann-la Roche Limited | $11,234 | 0.5% |